IL5 and asthma: Mepolizumab and reslizumab are anti-IL-5 monoclonal antibodies that have been shown to reduce asthma exacerbation rates by ~50% relative to placebo when used as add-on therapy in patients with exacerbation-prone severe eosinophilic asthma [9,10].